StreetAlpha.app
Home › Stocks › AXSM

Axsome Therapeutics, Inc. (AXSM)

Healthcare
$135.95
▼ −0.77%
LAST CLOSE · NOV 17

Axsome Therapeutics develops and sells medicines for depression, sleep disorders and migraine, with its headquarters in New York. It last closed at $135.95 on Nov 17, down 0.77% on the day. AXSM last reported earnings on Mon, Aug 10, 2026. The average 12-month price target from 10 analysts is $255.70 (+88.1% from the last close), with a high of $290.00 and a low of $220.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (9 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in AXSM, 0% of them bullish and 100% bearish. In the past 30 days there were 1 dark pool print totaling $949K, the largest $949K.

AI Auto Pilots
Is AXSM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$865.3M
+54.2% vs a year ago
Net income
−$157.3M
−18.2% margin
EPS (diluted)
−$3.03
Free cash flow
−$82.6M
−9.5% margin
Valuation
Market cap
$7.2B
52.6M shares
P/E
–
No P/E while losing money
Price to sales
8.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$313.9M
At Sep 30
Debt
$188.1M
At Sep 30
Shareholder equity
$105.4M
Shares outstanding
52.6M
At Oct 26
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $50.0M$50.0MFY2022FY2023: $270.6M$270.6MFY2023FY2024: $385.7M$385.7MFY2024FY2025: $638.5M$638.5MFY2025

From AXSM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Last report
Aug 10
2026 · Before the open (BMO)
Reported EPS
-$0.99
vs -$0.99 est. · inline
Year-ago EPS
—
Not on file
Options-implied move
±9.0%
Priced in before that report
Analyst consensus
Strong Buy
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
10firms
9 Buy1 Hold0 Sell
Each firm's latest rating on AXSM in the past 90 days
Average 12-month target
$255.70
▲ 88.1% upside

Based on 10 analysts who set a price target on AXSM in the past 90 days. The average target is $255.70, with a high of $290.00 and a low of $220.00, compared with the last close of $135.95.

Low $220.00Avg $255.70High $290.00
Blue marker: last close $135.95
Highest target$290.00
Average target$255.70
Lowest target$220.00
Latest rating changes
Morgan StanleyTarget lowered
Nov 13Hold$249 → $223
MizuhoTarget lowered
Nov 4Buy$316 → $272
Morgan StanleyTarget raised
Nov 3Hold$247 → $249
UBSMaintained
Nov 3Buy$239
RBC CapitalTarget lowered
Nov 3Buy$295 → $273
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget loweredHold$249 → $223
Nov 4MizuhoTarget loweredBuy$316 → $272
Nov 3Morgan StanleyTarget raisedHold$247 → $249
Nov 3UBSMaintainedBuy$239
Nov 3RBC CapitalTarget loweredBuy$295 → $273
Loading…

Technical Analysis

AXSM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 4% below its 20 day and 24% below its 50 day average. It is 45% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $134.58, and the nearest resistance the Pivot at $136.04.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 5.3%/day
Key levels
$260.1952 week high+91.4%
$196.56200 day average+44.6%
$195.85100 day average+44.1%
$168.6250 day average+24.0%
$147.49Swing high (Oct 29)+8.5%
$141.6520 day average+4.2%
$137.41Pivot R1+1.1%
$136.04Pivot+0.1%
$135.95Last close
$134.58Pivot S1−1.0%
$123.0252 week low−9.5%
$123.02Swing low (Nov 2)−9.5%
Indicators
RSI (14)36.63Weak, oversold below 30Neutral
MACD-7.93Above its signal lineBullish
Stochastic53.7Middle of its rangeNeutral
ADX (14)34.9Trending down
Williams %R-54.3Oversold below −80, overbought above −20Neutral
CCI (20)-68.0Oversold below −100, overbought above 100Neutral
Rate of change−2.6%Change over 10 sessionsBearish
ATR (14)$7.24Typical daily range, 5.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AXSM

What happened before

See how AXSM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AXSM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AXSM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
0
0%
Bearish
2
100%
Date span
Oct 8 – Nov 11
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$949K
Largest print
$949K
Loading…

AXSM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●242 buying vs 252 selling
  • ▲Held by funds +2.6 pts
  • ▼Funds holding -45
  • ▼Superinvestors: 2 added, 3 cut
  • ▼Put/call 0.73 to 1.25
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding465510−8.8%
In funds' top 10912−25.0%
Held by funds76.2%73.6%+2.6 pts
New / increased62 / 180133 / 160−17.4%
Reduced / sold out150 / 102156 / 42+27.3%
Put/call ratio1.250.73+71.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AXSM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AXSM is in one of them and how their past AXSM trades turned out.

AXSM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AXSM in an article yet. Here's the latest on the wider market.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company based in New York that develops medicines for disorders of the central nervous system. Its approved products treat major depressive disorder, excessive daytime sleepiness linked to sleep apnea or narcolepsy, and acute migraine in adults. The company markets these medicines to patients and prescribing doctors, and it is developing further treatments, including one for agitation linked to Alzheimer's disease.

Headquarters
New York, NY